华纳药厂：2025年前三季度，公司实现营业收入10.86亿元

Core Viewpoint - Warner Pharmaceuticals reported a slight increase in revenue and a significant rise in net profit for the first three quarters of 2025, indicating overall growth despite a decline in adjusted net profit [1] Financial Performance - The company achieved an operating revenue of 1.086 billion yuan, representing a year-on-year growth of 1.55% [1] - The net profit attributable to shareholders reached 207 million yuan, showing a year-on-year increase of 30.75% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 99 million yuan, reflecting a year-on-year decline of 26.52% [1] - After excluding the impact of share-based payments, the adjusted net profit attributable to shareholders was 133 million yuan, with a slight year-on-year decrease of 1.48% [1] Product Revenue Breakdown - Revenue from formulation products amounted to 805 million yuan, marking a year-on-year growth of 0.55% [1] - Revenue from raw materials and intermediates reached 262 million yuan, with a year-on-year increase of 2.06% [1]